Electra Therapeutics
Electra Therapeutics focuses on developing therapies that target the Signal Regulatory Protein (SIRP) family of receptors on immune cells. The company's portfolio of SIRP-directed antibodies is designed to address the underlying pathology across a range of diseases by selectively depleting pathological immune cells. The lead product candidate, ELA026, is a monoclonal antibody currently in pivotal clinical development for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition. Electra Therapeutics is also advancing a second program, ELA822, for use in immunology and inflammation conditions.
Domain
electra-therapeutics.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$183.0M
Founded
2018
Tech Stack (26 technologies)
Frequently Asked Questions
What technologies does Electra Therapeutics use?+
Electra Therapeutics uses 26 technologies including Elementor, Google Analytics, Google Tag Manager.
What industry is Electra Therapeutics in?+
Electra Therapeutics operates in the Biotechnology industry.
Where is Electra Therapeutics based?+
Electra Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026